The short version of lipodystrophy fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2025-12-03. Anything still debated is marked as such rather than presented as settled.
Growth hormone released from the pituitary stimulates the liver and other tissues to produce insulin-like growth factor 1, a stable circulating protein that serves as a practical marker of activity. Clinical studies therefore track IGF-1 concentrations alongside the hormone itself, and they commonly measure body composition with imaging rather than relying on body weight alone. Visceral adipose tissue, the fat surrounding abdominal organs, is quantified by computed tomography in the studies that supported approval. Adverse effects reported in trials include injection-site reactions, joint pain, and increases in blood glucose, which is why monitoring accompanies use.
Questions remain about how much of the observed fat reduction reflects direct GHRH-receptor signaling versus the downstream growth hormone and IGF-1 surge. It is also unclear whether the compound produces meaningful benefit in populations without lipodystrophy, since trials in cognitive impairment did not reach their stated goals. Long-term effects on glucose metabolism and on cardiovascular outcomes are not fully characterized. Published work generally describes effects on surrogate markers rather than on hard clinical endpoints, and independent replication of some findings is limited.
Tesamorelin is a synthetic peptide that belongs to the growth hormone-releasing hormone family and contains the same forty-four amino acid sequence as endogenous GHRH, extended at the amino terminus by a trans-3-hexenoyl group. That small fatty acid modification protects the peptide from rapid cleavage by dipeptidyl peptidase-4, the enzyme that shortens the half-life of native GHRH to only a few minutes. Chemically the compound is produced by solid-phase peptide synthesis, purified by chromatography, and supplied as a sterile lyophilized powder for reconstitution.
Regulatory approval in the United States came in 2010, when the Food and Drug Administration cleared the peptide for the reduction of excess abdominal fat in adults with HIV infection and associated lipodystrophy. The decision rested mainly on two randomized phase 3 trials that enrolled roughly eight hundred patients and ran for twenty-six weeks. Participants receiving active drug showed substantially greater declines in visceral adipose tissue than those receiving placebo, while total body weight changed comparatively little. A reformulated presentation was later approved, and the product has remained a niche therapy rather than a general weight-loss agent.
| Property | Value | Notes |
|---|---|---|
| Receptor target | Growth hormone-releasing hormone receptor | G-protein-coupled receptor expressed on pituitary somatotroph cells |
| Primary signaling route | Cyclic AMP and protein kinase A | Increases intracellular calcium and promotes hormone release |
| Downstream marker | Insulin-like growth factor 1 | Blood concentration used as an integrated activity indicator |
| Study endpoint | Change in visceral adipose tissue | Assessed with computed tomography in trial populations |
| Research status | Investigational outside the approved indication | Trials in cognitive impairment did not meet primary endpoints |
Studies of the compound rely on imaging and laboratory endpoints rather than on symptoms alone. Visceral adipose tissue is usually quantified by computed tomography or magnetic resonance imaging at the level of the abdomen, with waist circumference serving as a cheaper but less specific proxy. Blood work tracks insulin-like growth factor 1, fasting glucose, glycated hemoglobin, and lipid fractions. In the pivotal trials the imaging endpoint fell by roughly fifteen to twenty percent over six months, subcutaneous fat changed little, and the visceral fat returned toward baseline after treatment stopped, a pattern that shapes how clinicians discuss durability.
Whether the drug improves hard clinical outcomes is not settled. No completed trial has shown a reduction in heart attacks or strokes among treated patients, although a dedicated cardiovascular outcomes study has been discussed in the literature. Investigators have also examined hepatic fat in people with HIV and fatty liver disease, cognitive measures in small cohorts, and changes in bone density. Regulatory labeling emphasizes monitoring of insulin-like growth factor 1 because supraphysiologic levels raise questions about tissue growth, and the clinical significance of that signal remains an open question rather than a demonstrated harm.
Binding of tesamorelin to the growth hormone-releasing hormone receptor on anterior pituitary somatotrophs activates a Gs protein pathway, raises cyclic AMP, and triggers release of stored growth hormone into the bloodstream. Because the analogue resists dipeptidyl peptidase-4, its plasma residence time exceeds that of native GHRH, producing a larger and more sustained secretory signal. The released growth hormone then acts on the liver and peripheral tissues to raise insulin-like growth factor 1, which feeds back on the hypothalamus and pituitary. This axis explains both the intended effects on fat distribution and the biological markers used to track them.
Tesamorelin is a synthetic analog of growth hormone-releasing hormone, a peptide hormone produced by the hypothalamus. The molecule retains the 44-amino-acid sequence of human GHRH and carries a trans-3-hexenoyl modification at its N-terminus. This modification increases resistance to enzymatic degradation and extends the peptide's functional stability relative to native GHRH. The compound is supplied as a lyophilized powder for reconstitution and subcutaneous administration in clinical settings. Its development code was TH9507, and it belongs to the GHRH analog class. It is not a growth hormone product; instead, it acts upstream to stimulate endogenous growth hormone release.
Clinical interest in tesamorelin arose from the need to address visceral adiposity in people living with HIV. Antiretroviral therapy improved survival but was associated in some patients with central fat accumulation, altered lipid profiles, and metabolic complications. This condition, often called HIV-associated lipodystrophy, involves excess visceral adipose tissue that is difficult to manage through diet and exercise alone. Investigators evaluated tesamorelin because GHRH analogs can stimulate growth hormone secretion and influence fat distribution without direct liposuction or invasive procedures.
A Phase 3 program led to regulatory approval in the United States in 2010 for reduction of excess visceral abdominal fat in adults with HIV and lipodystrophy. Subsequent studies examined effects on liver fat, muscle area, and metabolic markers, with mixed findings for some endpoints. Long-term cardiovascular outcomes and effects on mortality remain uncertain because most trials were relatively short and focused on imaging-based fat measurements. Use in populations without HIV has been studied experimentally but is not part of the approved indication.
Stimulated growth hormone release leads to hepatic production of insulin-like growth factor 1, a key mediator of many growth hormone effects. In clinical studies, tesamorelin increased IGF-1 levels in a dose-dependent manner, although the response varies among individuals. The drug's effect on visceral fat is thought to involve growth hormone-mediated lipolysis and altered adipocyte metabolism. Muscle mass and lean body mass have also been assessed as secondary outcomes, but changes are generally smaller and less consistent than fat reductions.
Pharmacodynamic studies show that tesamorelin reduces visceral adipose tissue more than subcutaneous adipose tissue in the studied population. This selectivity may relate to differences in blood flow and hormone sensitivity between fat depots. Effects on glucose metabolism and insulin sensitivity have been investigated, with some trials reporting modest changes and others showing stability. The precise relationship between growth hormone exposure, IGF-1 levels, and visceral fat loss remains an active area of analysis.
Tesamorelin binds to growth hormone-releasing hormone receptors on somatotroph cells in the anterior pituitary. Receptor activation increases intracellular cyclic AMP and promotes synthesis and secretion of growth hormone. Because the peptide mimics endogenous GHRH, it amplifies the normal pulsatile release of growth hormone rather than providing exogenous growth hormone directly. This upstream action distinguishes tesamorelin from recombinant growth hormone preparations and from growth hormone secretagogues that act at different receptors.
Examples include the lateral femoral cutaneous nerve at the inguinal ligament and the middle cluneal nerves at the long posterior sacroiliac ligament. The compression even be dynamic, where compression may only be present during certain activities and positions. In deep gluteal syndrome, patients often have sciatic radiculopathy when sitting but not standing. Studies on compression and nerve function have found a dose-respondent relationship between pressure and duration. That is higher pressures and longer duration are associated with greater dysfunction. However even short but repeated periods of compression can also damage a nerve's microcirculatory environment. The amount of pressure required to cause nerve dysfunction starts at around 20mmHg where epineural venus blood flow is reduced. At 30mmHg anterograde and retrograde axonal transport is impaired. Between 30-50mmHg there will usually be changes in intraneural blood flow, axonal transport, and vascular permeability simultaneously. And at 80mmHg all intraneural blood flow is arrested, which results in a complete metabolic block. The amount of pressure required to disrupt intraneural blood flow isn't an absolute pressure but rather a function of the arterial blood pressure and perfusion pressure. Patients with higher blood pressures are somewhat protected from the effects of nerve entrapment by requiring higher pressures to interrupt intraneural blood flow.
Methamphetamine belongs to the substituted phenethylamine and substituted amphetamine chemical classes and as a drug acts as a serotonin–norepinephrine–dopamine releasing agent. It is related to the other dimethylphenethylamines as a positional isomer of these compounds, which share the common chemical formula C10H15N.
8 May to 2 July The PAVN began bombarding Ben Het Camp and by early June it was besieged by PAVN forces. The base received extensive air and artillery support On 26 June 180 ARVN soldiers were airlifted into the camp and by 28 June the ARVN were conducting sweeps outside the camp perimeter to push back the PAVN. PAVN losses were estimated to be in excess of 1,000 killed, while Allied losses were approximately 300 killed, including approximately 30 U.S.
Sources: en.wikipedia.org
== Diagnosis == BPDCN is suggested by a biopsy of skin lesions which reveals the infiltration by medium-sized blast (i.e. immature) cells into the dermis while sparing the epidermis. These cells exhibit irregular nuclei, fine chromatin, and at least one small nucleolus. Such blast cells may also be observed in the circulation, bone marrow, or other tissues and suggest BPDCN. However, the diagnosis of this disease requires determination that these cells are pDC blast cells rather than AML, T-cell lymphoblastic lymphoma (TCLL), or aggressive NK-cell leukemia (NKL) blast cells. Various studies have offered similar but not identical criteria to make this determination. All studies agree that pDC should have a typical plasmacytoid morphology and express a particular profile of marker proteins as detected by immunoassay and/or flow cytometry. However, the studies disagree on which marker proteins to profile. One study's profile assayed 1) CD4, CD56, CD123 (i.e. Interleukin-3 receptor, and TLC1, which are expressed on 80–100% of pDC but uncommon on AML, TCLL, or NKL blasts); 2) CD2AP and CLEC4C which are unique to pDC; and 3) myeloperoxidase, lysozyme, CD34, CD14, CD11c, and CD163 which are unique to AML, TCLL, or NKL blasts. Two other studies recommended assaying somewhat different sets of marker proteins.
=== Carrying of firearms on military bases === On April 2, 2026, Sec. Hegseth signed a memo allowing military personnel to carry personal firearms on military installations such as forts, camps, bases, naval yards and recruitment centers. His stated purpose was to allow personnel to defend themselves in the event of an attack and to support their second amendment rights. Supporters of the new policy, such as the family of slain Fort Hood specialist Vanessa Guillen have applauded it saying it would save lives. Concerns remain as to how the new policy will work in practice with state firearm laws, emergency response, and active threats.
== Staff == The Teaching and Research Staff (TRS) of the department consists of about 150 people (Professors, Associate Professors, Assistant Professors, Lecturers). Members EIB / ACC, administrative staff is 36 people.
The district performed 71 arrests for Cheese in the 2006-2007 school year. During the 2007-2008 school year from August to December the district performed 17 arrests. The number of children seeking treatment for use of Cheese remained steady. The paper reported that usage of Cheese spread from the northwest Dallas area and into areas outside of Dallas County. Deputy Chief Julian Bernal, the commander of the narcotics division of the Dallas Police, said that he encountered more White and Black teenagers using the drug. Michelle Hemm, the director of the Phoenix Academy of Dallas, believes that Cheese arrests decreased because users took more care to conceal the drugs or did not bring the drugs to schools for fear of detection.
Sources: en.wikipedia.org
May 25 2021 George Floyd protests New York City Mayoral candidate Shaun Donovan is arrested during a protest near the Holland Tunnel. Protests break out across the country to mark the first anniversary of the murder of George Floyd. Manhattan District Attorney Cyrus Vance Jr. announces that he has convened a grand jury in his criminal investigation into former President Trump over his real estate business, as well as the Trump Organization. COVID-19 pandemic COVID-19 vaccination – The CDC announces that 50% of the American adult population has been fully vaccinated. COVID-19 vaccines – Moderna says that their vaccine is 100% effective in teenagers between the ages of 12 and 17 years old. They say that they will seek approval from the FDA in early June. Michigan surpasses 19,000 confirmed deaths from COVID-19. May 26 – 2021 San Jose shooting: A mass shooting occurs at a Santa Clara Valley Transportation Authority rail yard in San Jose, California, leaving ten people dead, including the gunman who committed suicide. May 27 – The Department of Energy launches Perlmutter, the world's fastest AI-specialized supercomputer, with four exaflops of performance. May 30 2021 Hialeah shooting: A mass shooting in Hialeah, Florida leaves two dead and 20 injured. JBS S.A. cyberattack: A ransomware cyberattack hits several beef processing plants and slaughterhouses in Utah, Texas, Wisconsin, Nebraska, and Pennsylvania. Russian firm REvil has been accused of being the perpetrators of the attack.
=== Main group elements and lanthanides === The mechanisms of main group compounds of groups 13–18 are usually discussed in the context of organic chemistry (organic compounds are main group compounds, after all). Elements heavier than C, N, O, and F often form compounds with more electrons than predicted by the octet rule, as explained in the article on hypervalent molecules. The mechanisms of their reactions differ from organic compounds for this reason. Elements lighter than carbon (B, Be, Li) as well as Al and Mg often form electron-deficient structures that are electronically akin to carbocations. Such electron-deficient species tend to react via associative pathways. The chemistry of the lanthanides mirrors many aspects of chemistry seen for aluminium.
John Lewis & Partners announce further cuts to the number of its staff over the coming five years, with The Guardian reporting up to 11,000 jobs could go. The British Association of Dermatologists warns against the use of skincare products by children as young as eight, saying that to do so could leave them with irreversible skin damage. 28 January The hottest UK temperature in January is provisionally recorded by the Met Office, with a peak of 19.6 °C (67.3 °F) at Kinlochewe, Scottish Highlands, more than a degree higher than the previous record in 2003. The UK government announces plans to ban disposable vapes in an attempt to tackle the growing number of children taking up vaping. 29 January The King and the Princess of Wales are both discharged from hospital. Laurence Fox loses a High Court libel case with social media users he called paedophiles. Reporting on cases in family courts in England and Wales is extended to a further 16 venues following a trial at three locations. A University College London study of five cases of Alzheimer's disease suggests they could have been caused by a treatment in which the patients were injected with growth hormones from dead people, a treatment that was withdrawn in the mid-1980s. 30 January Lucy Letby has her initial request for permission to appeal against seven murder convictions and six attempted murder convictions refused by the Court of Appeal. HSBC is fined £57.4m by the Bank of England for "serious failings" over its measures to protect customer deposits.
Sources: en.wikipedia.org
It acts upstream at the pituitary receptor and depends on functioning somatotroph cells to produce any effect. Growth hormone injections bypass that step and deliver the hormone directly. The pharmacokinetic profiles and the resulting feedback on the body's own secretion therefore differ.
Insulin-like growth factor 1 is a downstream product of growth hormone action and changes more slowly than the hormone itself. Its blood concentration is used as an integrated indicator of whether the pathway has been stimulated. Interpretation requires attention to nutrition, illness, and other factors that shift IGF-1 independently.
No. The approved indication concerns excess visceral abdominal fat in adults with HIV infection and lipodystrophy, a specific clinical population. It is not cleared for general weight reduction or for cosmetic use. Studies in other groups remain investigational.
It is a laboratory-made peptide of forty-four amino acids whose sequence matches human growth hormone-releasing hormone, with a modified amino terminus. The modification is a short unsaturated fatty acid chain attached to the first residue. This change slows enzymatic breakdown and lengthens the time the peptide stays active in circulation.